The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML.
Acute Myeloid Leukemia (AML)
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML.
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
-
UCLA Medical Center, Los Angeles, California, United States, 90095
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States, 30912
University of Kansas Cancer Center, Fairway, Kansas, United States, 66205
New Jersey Hematology Oncology Associates, Brick, New Jersey, United States, 08724
Laura & Isaac Pe lmutter Cancer Center at NYU Langone Health, New York, New York, United States, 10016
Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States, 10021
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States, 77030
Baylor Scott & White Research Institute, Temple, Texas, United States, 76508
West Virginia University/Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States, 26506
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Bio-Path Holdings, Inc.,
Maro Ohanian, DO, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center
2024-12